Salsalate for T1D Neuropathy: Phase 2 Trial Results
June 21, 2024
-
1 min
5 Key Takeaways
-
1
Study evaluated salsalate for diabetic neuropathy in type 1 diabetes.
-
2
The trial showed no significant differences in the primary outcome.
-
3
Trends in nerve function improvements were observed in secondary measures.
-
4
Larger trials are needed to further evaluate salsalate's effects.
-
5
One investigator disclosed multiple associations with organizations and pharmaceutical companies.
A study presented at the American Diabetes Association Scientific Sessions evaluated the use of salsalate, an NFkB blocker, as a potential treatment for diabetic peripheral neuropathy and cardiovascular autonomic neuropathy in type 1 diabetes. The 12-month phase 2/3 randomized trial compared salsalate with a placebo, showing no significant differences in the primary outcome but trends in nerve function improvements in secondary measures. Larger trials are needed to further evaluate salsalate's effects on type 1 diabetes neuropathy.
Listen Tab content
